Song Li1, Yangsheng Yu2, Yinshi Yue2, Hongyan Liao2, Wanqin Xie2, Jessica Thai2, Ted R Mikuls3, Geoffrey M Thiele3, Michael J Duryee3, Harlan Sayles2, Jeffrey B Payne4, Lynell W Klassen3, James R O'Dell3, Zhixin Zhang5, Kaihong Su6. 1. Qilu Hospital of Shandong University, Ji'nan, Shandong, China, and University of Nebraska Medical Center, Omaha. 2. University of Nebraska Medical Center, Omaha. 3. Veterans Affairs Nebraska-Western Iowa Health Care System, and University of Nebraska Medical Center, Omaha. 4. University of Nebraska Medical Center, Omaha, and University of Nebraska Medical Center, Lincoln. 5. Sichuan University, Chengdu, China, University of Nebraska Medical Center, Omaha, and The Eppley Institute for Research in Cancer and Allied Diseases, Omaha. 6. University of Nebraska Medical Center, and The Eppley Institute for Research in Cancer and Allied Diseases, Omaha.
Abstract
OBJECTIVE: Anti-citrullinated protein antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA). However, the molecular basis for ACPA production is still unclear. The purpose of this study was to determine if circulating plasmablasts from RA patients produce ACPAs and whether Porphyromonas gingivalis facilitates the generation of ACPAs. METHODS: Using a single-cell antibody cloning approach, we generated 217 and 110 monoclonal recombinant antibodies from circulating plasmablasts from 7 RA patients and 4 healthy controls, respectively. Antibody reactivity with citrullinated antigens was tested by a second-generation anti-cyclic citrullinated peptide (anti-CCP) kit and by enzyme-linked immunosorbent assays (ELISAs) against citrullinated human antigens. Antibody reactivity with P gingivalis was tested by ELISAs against outer membrane antigens (OMAs) and citrullinated enolase from P gingivalis. RESULTS: Approximately 19.5% of plasmablast-derived antibodies from anti-CCP-positive RA patients, but none from 1 anti-CCP-negative RA patient or the healthy controls, specifically recognized citrullinated antigens. The immunoglobulin genes encoding these ACPAs were highly mutated, with increased ratios of replacement mutations to silent mutations, suggesting the involvement of active antigen selection in ACPA generation. Interestingly, 63% of the ACPAs cross-reacted with OMAs and/or citrullinated enolase from P gingivalis. The reactivity of ACPAs against citrullinated proteins from P gingivalis was confirmed by immunoblotting and mass spectrometry. Furthermore, some germline-reverted ACPAs retained their reactivity with P gingivalis antigens but completely lost their reactivity with citrullinated human antigens. CONCLUSION: These results suggest that circulating plasmablasts in RA patients produce ACPAs and that this process may be facilitated by anti-P gingivalis immune responses.
OBJECTIVE: Anti-citrullinated protein antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA). However, the molecular basis for ACPA production is still unclear. The purpose of this study was to determine if circulating plasmablasts from RApatients produce ACPAs and whether Porphyromonas gingivalis facilitates the generation of ACPAs. METHODS: Using a single-cell antibody cloning approach, we generated 217 and 110 monoclonal recombinant antibodies from circulating plasmablasts from 7 RApatients and 4 healthy controls, respectively. Antibody reactivity with citrullinated antigens was tested by a second-generation anti-cyclic citrullinated peptide (anti-CCP) kit and by enzyme-linked immunosorbent assays (ELISAs) against citrullinated human antigens. Antibody reactivity with P gingivalis was tested by ELISAs against outer membrane antigens (OMAs) and citrullinated enolase from P gingivalis. RESULTS: Approximately 19.5% of plasmablast-derived antibodies from anti-CCP-positive RApatients, but none from 1 anti-CCP-negative RApatient or the healthy controls, specifically recognized citrullinated antigens. The immunoglobulin genes encoding these ACPAs were highly mutated, with increased ratios of replacement mutations to silent mutations, suggesting the involvement of active antigen selection in ACPA generation. Interestingly, 63% of the ACPAs cross-reacted with OMAs and/or citrullinated enolase from P gingivalis. The reactivity of ACPAs against citrullinated proteins from P gingivalis was confirmed by immunoblotting and mass spectrometry. Furthermore, some germline-reverted ACPAs retained their reactivity with P gingivalis antigens but completely lost their reactivity with citrullinated human antigens. CONCLUSION: These results suggest that circulating plasmablasts in RApatients produce ACPAs and that this process may be facilitated by anti-P gingivalis immune responses.
Authors: Kasia Owczarczyk; Preeti Lal; Alexander R Abbas; Kristen Wolslegel; Cecile T J Holweg; Wolfgang Dummer; Ariella Kelman; Paul Brunetta; Nicholas Lewin-Koh; Marco Sorani; Diane Leong; Paul Fielder; David Yocum; Carole Ho; Ward Ortmann; Michael J Townsend; Timothy W Behrens Journal: Sci Transl Med Date: 2011-09-21 Impact factor: 17.956
Authors: Sarah A Oracki; Jennifer A Walker; Margaret L Hibbs; Lynn M Corcoran; David M Tarlinton Journal: Immunol Rev Date: 2010-09 Impact factor: 12.988
Authors: Maria F Bellatin; Mei Han; Margarita Fallena; Lin Fan; Donglan Xia; Nancy Olsen; Valerie Branch; David Karp; Peter Stastny Journal: J Immunol Date: 2012-02-15 Impact factor: 5.422
Authors: Natalia Wegner; Karin Lundberg; Andrew Kinloch; Benjamin Fisher; Vivianne Malmström; Marc Feldmann; Patrick J Venables Journal: Immunol Rev Date: 2010-01 Impact factor: 12.988
Authors: E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel Journal: Arthritis Rheum Date: 2000-08
Authors: Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers Journal: J Clin Invest Date: 2006-04 Impact factor: 14.808
Authors: Serra E Elliott; Sarah Kongpachith; Nithya Lingampalli; Julia Z Adamska; Bryan J Cannon; Lisa K Blum; Michelle S Bloom; Matthew Henkel; Mandy J McGeachy; Larry W Moreland; William H Robinson Journal: Clin Immunol Date: 2020-02-05 Impact factor: 3.969
Authors: Sarah Kongpachith; Nithya Lingampalli; Chia-Hsin Ju; Lisa K Blum; Daniel R Lu; Serra E Elliott; Rong Mao; William H Robinson Journal: Arthritis Rheumatol Date: 2019-02-27 Impact factor: 10.995
Authors: Philip J Titcombe; Gustaf Wigerblad; Natalie Sippl; Na Zhang; Anna K Shmagel; Peter Sahlström; Yue Zhang; Laura O Barsness; Yogita Ghodke-Puranik; Azar Baharpoor; Monika Hansson; Lena Israelsson; Karl Skriner; Timothy B Niewold; Lars Klareskog; Camilla I Svensson; Khaled Amara; Vivianne Malmström; Daniel L Mueller Journal: Arthritis Rheumatol Date: 2018-10-18 Impact factor: 10.995
Authors: M Kristen Demoruelle; Emily Bowers; Lauren J Lahey; Jeremy Sokolove; Monica Purmalek; Nickie L Seto; Michael H Weisman; Jill M Norris; Mariana J Kaplan; V Michael Holers; William H Robinson; Kevin D Deane Journal: Arthritis Rheumatol Date: 2018-03-02 Impact factor: 10.995
Authors: Jing Shi; Erika Darrah; Gary P Sims; Tomas Mustelin; Kevon Sampson; Maximilian F Konig; Clifton O Bingham; Antony Rosen; Felipe Andrade Journal: Ann Rheum Dis Date: 2017-10-25 Impact factor: 19.103
Authors: Hans Ulrich Scherer; Tom W J Huizinga; Gerhard Krönke; Georg Schett; Rene E M Toes Journal: Nat Rev Rheumatol Date: 2018-02-08 Impact factor: 20.543